Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada

References

• Canadian Institute for Health Information. Inpatient hospitalizations, surgeries and childbirth indicators in 2013–2014. Ottawa (ON); 2019. Available from: https://secure.cihi.ca/free_products/CAD_Hospitalization%20and%20Childbirth_Infosheet_ENrev-web.pdf. Accessed March 14, 2023.
   Google Scholar
• Statistics Canada. Leading causes of death, total population, by age group. Ottawa (ON); 2019. Available from: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310039401. Accessed March 14, 2023.
   Google Scholar
• Kassebaum NJ, Arora M, Barber RM, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1603–1658.
   PubMed Web of Science ®Google Scholar
• Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for. 249 causes of death, 1980–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1459–1544.
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Davignon J, Hermans MP, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13:26. doi:10.1186/1475-2840-13-26
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350–1357. doi:10.1001/jama.2010.1322
   PubMed Web of Science ®Google Scholar
• Nambi V, Bhatt DL. Primary prevention of atherosclerosis: time to take a selfie? J Am Coll Cardiol. 2017;70:2992–2994. doi:10.1016/j.jacc.2017.10.068
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Venkataramani AS, Bhatt DL. Moving toward global primordial prevention in cardiovascular disease: the heart of the matter. J Am Coll Cardiol. 2015;66:1535–1537. doi:10.1016/j.jacc.2015.08.027
   PubMed Web of Science ®Google Scholar
• Chait A, Ginsberg HN, Vaisar T, Heinecke JW, Goldberg IJ, Bornfeldt KE. Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease. Diabetes. 2020;69:508–516. doi:10.2337/dbi19-0007
   PubMed Web of Science ®Google Scholar
• Dash S, Leiter LA. Residual cardiovascular risk among people with diabetes. Diabetes Obes Metab. 2019;21(Suppl 1):28–38. doi:10.1111/dom.13646
   PubMedGoogle Scholar
• Klempfner R, Erez A, Sagit BZ, et al. Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two-year follow-up of the bezafibrate infarction prevention study and registry. Circ Cardiovasc Qual Outcomes. 2016;9:100–108. doi:10.1161/CIRCOUTCOMES.115.002104
   PubMed Web of Science ®Google Scholar
• Libby P. Triglycerides on the rise: should we swap seats on the seesaw? Eur Heart J. 2015;36:774–776. doi:10.1093/eurheartj/ehu500
   PubMed Web of Science ®Google Scholar
• Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased cardiovascular risk in hypertriglyceridemic patients with statin-controlled LDL cholesterol. J Clin Endocrinol Metab. 2018;103:3019–3027. doi:10.1210/jc.2018-00470
   PubMed Web of Science ®Google Scholar
• Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes Metab. 2019;21:366–371. doi:10.1111/dom.13537
   PubMed Web of Science ®Google Scholar
• Toth PP, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018;7:e008740. doi:10.1161/JAHA.118.008740
   PubMed Web of Science ®Google Scholar
• Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72:330–343. doi:10.1016/j.jacc.2018.04.061
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–1574.
   PubMed Web of Science ®Google Scholar
• Hegele RA, Gidding SS, Ginsberg HN, et al. Nonstatin low-density lipoprotein- lowering therapy and cardiovascular risk reduction-statement from ATVB council. Arterioscler Thromb Vasc Biol. 2015;35:2269–2280. doi:10.1161/ATVBAHA.115.306442
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861.
   PubMed Web of Science ®Google Scholar
• Anderson TJ, Gregoire J, Pearson GJ, et al. Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016;2016(32):1263–1282. doi:10.1016/j.cjca.2016.07.510
   Google Scholar
• Bhatt DL, Budoff MJ, Mason RP. A Revolution in Omega-3 Fatty Acid Research. J Am Coll Cardiol. 2020;76:2098–2101. doi:10.1016/j.jacc.2020.09.005
   PubMed Web of Science ®Google Scholar
• Mason RP, Libby P, Bhatt DL. Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid. Arterioscler Thromb Vasc Biol. 2020;40:1135–1147. doi:10.1161/ATVBAHA.119.313286
   PubMed Web of Science ®Google Scholar
• Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41:3925–3932. doi:10.1093/eurheartj/ehaa652
   PubMed Web of Science ®Google Scholar
• Mason RP, Jacob RF, Shrivastava S, Sherratt SCR, Chattopadhyay A. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochim Biophys Acta. 2016;1858:3131–3140. doi:10.1016/j.bbamem.2016.10.002
   PubMed Web of Science ®Google Scholar
• Nelson JR, Wani O, May HT, Budoff M. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques. Vascul Pharmacol. 2017;91:1–9. doi:10.1016/j.vph.2017.02.004
   PubMed Web of Science ®Google Scholar
• Sherratt SCR, Mason RP. Eicosapentaenoic acid and docosahexaenoic acid have distinct membrane locations and lipid interactions as determined by X-ray diffraction. Chem Phys Lipids. 2018;212:73–79. doi:10.1016/j.chemphyslip.2018.01.002
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22. doi:10.1056/NEJMoa1812792
   PubMed Web of Science ®Google Scholar
• The Conference Board of Canada. Mortality due to heart disease and stroke; 2015. Available from: https://www.conferenceboard.ca/hcp/provincial/health/heart.aspx?AspxAutoDetectCookieSupport=1. Accessed March 14, 2023.
   Google Scholar
• Government of Canada. Stroke in Canada; 2016. Available from: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/stroke-in-canada.html. Accessed March 14, 2023.
   Google Scholar
• Public Health Agency of Canada. Heart Disease in Canada. Public Health Agency of Canada; 2017.
   Google Scholar
• Public Health Agency of Canada. Economic Burden of Ilness in Canada 2005–2008. Ottawa (ON): Public Health Agency of Canada; 2014.
   Google Scholar
• CADTH. Guidelines for the Economic Evaluation of Health Technologies. 4th ed. Ottawa, Ontario (Canada): CADTH Methods and Guidelines; 2017.
   Google Scholar
• McGregor M. Cost-utility analysis: use QALYs only with great caution. CMAJ. 2003;168:433–434.
   PubMed Web of Science ®Google Scholar
• Stone Neil J, Robinson Jennifer G, Lichtenstein Alice H, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation. 2013;2014(129):S1–S45.
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Pharmacoeconomic review report for Praluent; 2016.
   Google Scholar
• Ministry of Health and Long-Term Care of Ontario. Ontario drug benefit formulary/comparative drug index - formulary search; 2019. Available from: https://www.formulary.health.gov.on.ca/formulary/. Accessed March 14, 2023.
   Google Scholar
• Statistics Canada. Consumer price index, health and personal care, by province (monthly); 2016. Available from: https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1810000413. Accessed March 14, 2023.
   Google Scholar
• Kaul P, Armstrong PW, Chang WC, et al. Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in global utilization of streptokinase and t-PA for occluded coronary arteries (GUSTO)- I. Circulation. 2004;110:1754–1760. doi:10.1161/01.CIR.0000142671.06167.91
   PubMed Web of Science ®Google Scholar
• Ministry of Health and Long Term Care. Ontario case costing - cost analysis tool, health data branch web portal; 2017. Available from: http://hsim.health.gov.on.ca/hdbportal/2015. Accessed March 14, 2023.
   Google Scholar
• Henk HJ, Paoli CJ, Gandra SR. A retrospective study to examine healthcare costs related to cardiovascular events in individuals with hyperlipidemia. Adv Ther. 2015;32:1104–1116. doi:10.1007/s12325-015-0264-7
   PubMed Web of Science ®Google Scholar
• Anis H, Sun H, Singh S, Woolcott J, Nosyk B, Brisson M. A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy. Pharmacoeconomics. 2006;24:387–400. doi:10.2165/00019053-200624040-00008
   PubMed Web of Science ®Google Scholar
• Kodera S, Morita H, Kiyosue A, Ando J, Komuro I. Cost-effectiveness of statin plus eicosapentaenoic acid combination therapy for cardiovascular disease prevention in japanese patients with hypercholesterolemia - an analysis based on the Japan eicosapentaenoic acid lipid intervention study (JELIS). Circ J. 2018;82:1076–1082. doi:10.1253/circj.CJ-17-0995
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090–1098. doi:10.1016/S0140-6736(07)60527-3
   PubMed Web of Science ®Google Scholar
• Philip S, Chowdhury S, Nelson JR, Benjamin everett P, Hulme-Lowe CK, Schmier JK. A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States. J Med Econ. 2016;19:1003–1010. doi:10.1080/13696998.2016.1207652
   PubMed Web of Science ®Google Scholar
• Gao L, Moodie M, Li SC. The cost-effectiveness of omega-3 polyunsaturated fatty acids The Australian healthcare perspective. Eur J Intern Med. 2019;67:70–77. doi:10.1016/j.ejim.2019.07.001
   PubMed Web of Science ®Google Scholar
• Marquina C, Zomer E, Vargas-Torres S, et al. Novel treatment strategies for secondary prevention of cardiovascular disease: a systematic review of cost-effectiveness. Pharmacoeconomics. 2020;38:1095–1113. doi:10.1007/s40273-020-00936-0
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD, DePalma SM. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American college of cardiology task force on clinical expert consensus documents. J Am Coll Cardiol. 2016;68:92–125. doi:10.1016/j.jacc.2016.03.519
   PubMed Web of Science ®Google Scholar
• O’Reilly DJ, Xie F, Pullenayegum E, et al. Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada. Qual Life Res. 2011;20:939–943. doi:10.1007/s11136-010-9828-9
   PubMed Web of Science ®Google Scholar
• Stevanovic J, Pechlivanoglou P, Kampinga MA, Krabbe PF, Postma MJ. Multivariate meta-analysis of preference-based quality of life values in coronary heart disease. PLoS One. 2016;11:e0152030. doi:10.1371/journal.pone.0152030
   PubMed Web of Science ®Google Scholar
• National Clinical Guideline Centre. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. London: National Clinical Guideline Centre; 2014. Available from: https://www.nice.org.uk/guidance/cg181/evidence/lipid‐modification‐update‐appendices‐243786638. Accessed March 14, 2023.
   Google Scholar
• Sullivan PW, Ghushchyan VH. EQ-5D scores for diabetes-related comorbidities. Value Health. 2016;19:1002–1008. doi:10.1016/j.jval.2016.05.018
   PubMed Web of Science ®Google Scholar
• Christensen HN, Olsson U, From J, Breivik H. Opioid-induced constipation, use of laxatives, and health-related quality of life. Scand J Pain. 2016;11:104–110. doi:10.1016/j.sjpain.2015.12.007
   PubMed Web of Science ®Google Scholar
• National Institute for Health and care Excellence. Chronic obstructive pulmonaty disease in over 16s: diagnosis and management - Econominc model report”. NICE guideline [NG115]; 2018.
   Google Scholar
• Steg PG, Alam S, Chiang CE, et al. Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart. 2012;98:195–201. doi:10.1136/heartjnl-2011-300550
   PubMed Web of Science ®Google Scholar
• Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care. 2000;38:583–637. doi:10.1097/00005650-200006000-00004
   PubMed Web of Science ®Google Scholar